Journal: bioRxiv

Article Title: Ex vivo drug testing in metastatic biopsies reveals patient-specific vulnerabilities to cancer targeting and immune activating drugs

doi: 10.64898/2026.02.06.704037

Figure Lengend Snippet: ( A ) Schematic illustration of the drug response assay. Created with BioRender.com. TME, tumor microenvironment; IF, immunofluorescence. ( B ) Cellular composition of malignant pleural effusions (MPEs) from five NSCLC patients as determined by flow cytometry. ( C ) ATP-based viability of a MPE in different culture media. Each dot represents the mean ± standard deviation (shaded envelope) of n = 5 technical replicates from one representative donor (P179). ( D ) Flow cytometric analysis of MPE viability in HPLM medium. Each dot represents an individual donor (n = 5). P-values were calculated using Wilcoxon matched-pairs signed rank test. ( E ) Log2-fold change (Log2FC) in cellular composition of MPEs after 5 days in HPLM medium compared to baseline, analyzed by flow cytometry. Each dot represents an individual donor. Samples from n = 5 donors were measured. To illustrate fold changes, cell fractions below the 2%-detection limit were excluded from analysis. P-values were determined using a one-sample Wilcoxon test against zero. ( F ). As for (E), but for marker expression of cancer cells (PD-L1, Nectin-4, TROP2) and T cells (PD-1). ( G ) Cytokine secretion and immune checkpoint expression of MPEs (n = 5) after 5 days of ex vivo culture. Color scale represents Z-scores normalized across patients for each cytokine or marker. nMFI, mean fluorescence intensity normalized to fluorescence minus one (FMO) control. ( H ) Relative cell loss of two non-adherent cell lines following the optimized IHC liquid handling protocol. Dots represent outliers among technical replicate wells across n = 3 biological replicates (384-well plates). P-values were calculated using a one-sample Wilcoxon test. ( I ) Pseudocolor plot depicting MFIs of CD45 and EpCAM signal for all segmented masks of a spike-in of MCF-7 cells in lymph node cells. Cell populations were classified based on manual gating. ( J ) Number of cancer (left) and immune cells (right) detected using our image analysis pipeline. Box plots represent data of n = 10 technical replicate wells. ( K ) Cancer cell fractions in malignant pleural effusions (MPEs) from NSCLC patients (n = 5), determined by EpCAM-based immunocytochemistry. The dashed line indicates the detection limit (10 cells per well) of the drug response assay.

Article Snippet: Cells were resuspended in 100 μL of FACS buffer (1% (w/v) BSA, 2 mM EDTA in DPBS) per 1 x 10 6 cells and stained using the following antibodies: Alexa Fluor® 488 anti-human CD3, clone HIT3a (BioLegend, #300319, RRID:AB_493690), PerCP/Cyanine5.5 anti-human CD14, clone HCD14 (BioLegend, # 325621, RRID:AB_893252), PE anti-human CD279 (PD-1), clone EH12.2H7 (BioLegend, # 329905, RRID:AB_940481), PE/Cyanine7anti-human CD11c, clone Bu15 (BioLegend, # 337215, RRID:AB_2129791), APC-Vio770 anti-human CD19, clone LT19 (1:50; Miltenyi Biotec, # 130-098-073, RRID:AB_2661296), Brilliant VioletTM 421 anti-human CD45, clone 2D1 (BioLegend, # 368522, RRID:AB_2687375), Brilliant VioletTM 605 anti-human HLA-DR, clone L243 (BioLegend, # 307639, RRID:AB_11219187), Brilliant VioletTM 785 anti-human CD56 (NCAM), clone 167 (BioLegend, # 362549, RRID:AB_2566058), Alexa Fluor® 488 anti-human CD326 (EpCAM), clone Co17-1A (BioLegend, # 369808, RRID:AB_2650905), PE anti-human TROP2, REAfinityTM (1:50; Miltenyi Biotec, # 130-115-097, RRID:AB_2726914), APC anti-human Nectin-4, REAfinityTM (1:50; Miltenyi Biotec, # 130-116-103, RRID:AB_2727350), Brilliant VioletTM 421 anti-human CD274 (B7-H1, PD-L1), clone 29E.2A3 (BioLegend, # 329714, RRID:AB_2563852), Brilliant VioletTM 785 anti-human CD45, clone HI30 (BioLegend, # 304048, RRID:AB_2563129), Zombie AquaTM (1:1,000; BioLegend, # 423102), Zombie NIRTM (1:500; BioLegend, # 423106).

Techniques: Immunofluorescence, Flow Cytometry, Standard Deviation, Marker, Expressing, Ex Vivo, Fluorescence, Control, Immunocytochemistry

Journal: Frontiers in Immunology

Article Title: Osteoclasts affect the anti-cancer activity of NK cells

doi: 10.3389/fimmu.2026.1730283

Figure Lengend Snippet: Expression of NK cell receptor ligands by OCs by flow cytometry. The graph shows the expression levels of PVR and Nectin-2, respectively ligands of DNAM-1 and TIGIT on OCs and on OC+NK cells after 3 days (A) . Characterization of NID-1 ligand of NKp44 and B7H6 ligand of NKp30 on OCs and on OCs+NK cells, with A549s and with both NK cells+A549s (B) . N = 6 experiments. Groups were compared using a one-way repeated measures analysis of variance with post hoc Tukey test (* p < 0.05; ** p < 0.01).

Article Snippet: After 10 days, spheroid-like structures were originated, then dissociated by ACCUTASE and analyzed by flow cytometry through the staining with the following anti-human monoclonal antibodies CD133 PE-Vio770, Nectin-2 PE, Nectin-4 Vio Bright V423 (Miltenyi Biotec, Bergisch Gladbach, Germany), CXCR4 APC (BD Bioscence, Franklin Lakes, New Jersey, USA), PVR BV510 (Biolegend, San Diego, USA).

Techniques: Expressing, Flow Cytometry

Journal: Frontiers in Immunology

Article Title: Osteoclasts affect the anti-cancer activity of NK cells

doi: 10.3389/fimmu.2026.1730283

Figure Lengend Snippet: Analysis of CD133 + /CXCR4 + CSC subset. Evaluation of the CSC CD133 + /CXCR4 + subset of A549s, in co-culture with NK cells, OCs and with both OCs and NK cells (A) . Evaluation of expression levels of Nectin-2 (ligand of TIGIT and DNAM-1) (B) and Nectin-4 (ligand of TIGIT) (C) on CD133 + cells, in co-culture with NK cells, OCs and with NK cells+OCs (B, C) . N = 5 experiments. Groups were compared using a one-way repeated measures analysis of variance with post hoc Tukey test (* p < 0.05; ** p < 0.01).

Article Snippet: After 10 days, spheroid-like structures were originated, then dissociated by ACCUTASE and analyzed by flow cytometry through the staining with the following anti-human monoclonal antibodies CD133 PE-Vio770, Nectin-2 PE, Nectin-4 Vio Bright V423 (Miltenyi Biotec, Bergisch Gladbach, Germany), CXCR4 APC (BD Bioscence, Franklin Lakes, New Jersey, USA), PVR BV510 (Biolegend, San Diego, USA).

Techniques: Co-Culture Assay, Expressing